AstraZeneca Raised Its 2024 Guidance: Now Expects Total Revenue And Core EPS Both Expected To Increase By A Mid-Teens Percentage (Previously Anticipated To Rise By A Low Double-Digit To Low-Teens Percentage)
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca has raised its 2024 guidance, now expecting total revenue and core EPS to increase by a mid-teens percentage, up from the previously anticipated low double-digit to low-teens percentage. This is due to strong growth in product sales and alliance revenue.
July 25, 2024 | 6:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca has raised its 2024 guidance, now expecting total revenue and core EPS to increase by a mid-teens percentage, up from the previously anticipated low double-digit to low-teens percentage. This upgrade is driven by strong growth in product sales and alliance revenue.
The raised guidance indicates stronger-than-expected performance, which is likely to positively impact investor sentiment and drive the stock price up in the short term. The increase in total revenue and core EPS expectations reflects robust underlying growth in product sales and alliance revenue.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100